HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

nemorubicin

antineoplastic; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Geroni, Cristina: 2 articles (01/2007 - 02/2005)
2.	Caruso, Michele: 1 article (12/2012)
3.	Mazzini, Stefania: 1 article (12/2012)
4.	Mondelli, Rosanna: 1 article (12/2012)
5.	Scaglioni, Leonardo: 1 article (12/2012)
6.	Sirtori, Federico Riccardi: 1 article (12/2012)
7.	Sessa, Cristiana: 1 article (01/2007)
8.	Valota, Olga: 1 article (01/2007)
9.	Battaglia, Rosangela: 1 article (02/2005)
10.	Fantin, Marianna: 1 article (02/2005)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2007 - "Another way to improve selectivity is to activate the drug at the tumor site, a good example of which is provided by Nemorubicin (2\"-(S)-methoxymorpholinodoxorubicin hydrochloride) in hepatocellular carcinoma. " 12/15/2012 - "The antitumor anthracycline nemorubicin is converted by human liver microsomes to a major metabolite, PNU-159682 (PNU), which was found to be much more potent than its parent drug toward cultured tumor cells and in vivo tumor models. " 01/01/2007 - "The favorable characteristics of Nemorubicin in terms of broad spectrum of significant antitumor activity in liver malignancies models, lower cardiotoxicity than Doxorubicin, make Nemorubicin a promising third-generation anthracycline, suitable for intrahepatic administration."
2.	Hepatocellular Carcinoma (Hepatoma) 01/01/2007 - "Another way to improve selectivity is to activate the drug at the tumor site, a good example of which is provided by Nemorubicin (2\"-(S)-methoxymorpholinodoxorubicin hydrochloride) in hepatocellular carcinoma. " 02/15/2005 - "Nemorubicin (3'-deamino-3'-[2''(S)-methoxy-4''-morpholinyl]doxorubicin; MMDX) is an investigational drug currently in phase II/III clinical testing in hepatocellular carcinoma. "
3.	Cardiotoxicity 01/01/2007 - "The favorable characteristics of Nemorubicin in terms of broad spectrum of significant antitumor activity in liver malignancies models, lower cardiotoxicity than Doxorubicin, make Nemorubicin a promising third-generation anthracycline, suitable for intrahepatic administration."

Related Drugs and Biologics

1.	Anthracyclines
2.	Doxorubicin (Adriamycin)
3.	Investigational Drugs
4.	3'- deamino- 3'',4'- anhydro- (2''- methoxy- 3''- oxy- 4''- morpholinyl)doxorubicin
5.	methoxy-morpholinyl-doxorubicin